Ekonomski rezultati

Restrictive blood transfusion practices are associated with improved patient outcomes. (otvara novi prozor)

Goodnough LT, Maggio P, Hadhazy E, Shieh L, Hernandez-Boussard T, Khari P, Shah N.

Izvor‎: Transfusion 2014;54(10 Pt 2):2753-9.

Indeks‎: PubMed 24995770

DOI‎: 10.1111/trf.12723

https://www.ncbi.nlm.nih.gov/pubmed/24995770 (otvara novi prozor)

Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. (otvara novi prozor)

Leahy MF, Hofmann A, Towler S, Trentino KM, Burrows SA, Swain SG, Hamdorf J, Gallagher T, Koay A, Geelhoed GC, Farmer SL.

Izvor‎: Transfusion 2017;57(6):1347-58.

Indeks‎: PubMed 28150313

DOI‎: 10.1111/trf.14006

https://www.ncbi.nlm.nih.gov/pubmed/28150313 (otvara novi prozor)

Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. (otvara novi prozor)

MacLaren R, Sullivan PW.

Izvor‎: Value Health 2005;8(2):105-16.

Indeks‎: PubMed 15804319

DOI‎: 10.1111/j.1524-4733.2005.04006.x

https://www.ncbi.nlm.nih.gov/pubmed/15804319 (otvara novi prozor)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (otvara novi prozor)

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

Izvor‎: Transfusion 2015;55(12):2807-15.

Indeks‎: PubMed 26264557

DOI‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 (otvara novi prozor)

Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. (otvara novi prozor)

Nardi G, Agostini V, Rondinelli B, Russo E, Bastianini B, Bini G, Bulgarelli S, Cingolani E, Donato A, Gambale G, Ranaldi G

Izvor‎: Crit Care 2015;19:83.

Indeks‎: PubMed 25880548

DOI‎: 10.1186/s13054-015-0817-9

https://www.ncbi.nlm.nih.gov/pubmed/25880548 (otvara novi prozor)

The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. (otvara novi prozor)

Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, Cook L, Kawahara T, Perel P, Prieto-Merino D, Ramos M, Cairns J, Guerriero C.

Izvor‎: Health Technol Assess 2013;17(10):1-79.

Indeks‎: PubMed 23477634

DOI‎: 10.3310/hta17100

https://www.ncbi.nlm.nih.gov/pubmed/23477634 (otvara novi prozor)

Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. (otvara novi prozor)

Stein DM, Dutton RP, Kramer ME, Scalea TM.

Izvor‎: J Trauma 2009;66(1):63-72.

Indeks‎: PubMed 19131807

DOI‎: 10.1097/TA.0b013e318191bc8a

https://www.ncbi.nlm.nih.gov/pubmed/19131807 (otvara novi prozor)

Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. (otvara novi prozor)

Zilberberg MD, Shorr AF.

Izvor‎: BMC Health Serv Res 2007;7:138.

Indeks‎: PubMed 17764560

DOI‎: 10.1186/1472-6963-7-138

https://www.ncbi.nlm.nih.gov/pubmed/17764560 (otvara novi prozor)

INTENZIVNA NEGA

Ekonomski rezultati

srpski (latinica)

Ekonomski rezultati

https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Restrictive blood transfusion practices are associated with improved patient outcomes. (otvara novi prozor)

Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. (otvara novi prozor)

Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. (otvara novi prozor)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (otvara novi prozor)

Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. (otvara novi prozor)

The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. (otvara novi prozor)

Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. (otvara novi prozor)

Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. (otvara novi prozor)

Kontakt s lokalnim predstavnicima (OOB)

Medicinske informacije

Filmovi

Ekonomski rezultati

Izaberi jezik

Podeli